Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-17), Alvotech's 14-Day RSI is 41.07.
The industry rank for Alvotech's 14-Day RSI or its related term are showing as below:
OISE:ALVO's 14-Day RSI is ranked better than 73.35% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 51.8
vs OISE:ALVO: 41.07
Alvotech (OISE:ALVO) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Alvotech 14-Day RSI Related Terms
OISE:ALVO vs PAHC, COLL, XERS: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alvotech 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alvotech's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Alvotech's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alvotech (OISE:ALVO) has a 14-Day RSI of 41.07 as of Jul. 17, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Alvotech and its competitors. According to the industry distribution chart, Alvotech ranks #279 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Alvotech's 14-Day RSI too high?
Alvotech's current 14-Day RSI is 41.07. The Drug Manufacturers industry median 14-Day RSI is 51.80. Alvotech's value of 41.07 is 20.7% below this industry median. Based on the distribution chart, Alvotech ranks #279 out of 1047 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alvotech has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's 14-Day RSI compare to PAHC and COLL?
According to the Drug Manufacturers industry distribution chart, Alvotech ranks #279 out of 1047 companies for 14-Day RSI. This puts Alvotech in the upper half of its industry. The industry median 14-Day RSI is 51.80. Alvotech's value of 41.07 is 20.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 51.80, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alvotech's current 14-Day RSI of 41.07 is 20.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Alvotech and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 51.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alvotech's current 14-Day RSI is 41.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,325.70, compared to a current price of kr421.00 — trading 81.9% below its estimated fair value. The current 14-Day RSI is 41.07 and 20.7% below the Drug Manufacturers industry median of 51.80. Alvotech's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current 14-Day RSI is 41.07 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alvotech (OISE:ALVO) Overvalued in 2026?
Based on GuruFocus' analysis, Alvotech stock appears to be undervalued.
The current stock price of kr421.00 is trading 81.9% below its estimated GF Value™ of kr2,325.70.
GuruFocus considers Alvotech to be Possible Value Trap.
Key valuation signals for OISE:ALVO:
14-Day RSI: 41.07
GF Value™: kr2,325.70 vs. price of kr421.00 (81.9% below fair value)
Industry Position: 20.7% below the Drug Manufacturers median (#279 of 1047)
No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
54GF Score
Get the complete analysis for OISE:ALVO
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OISE:ALVO has been successfully added to your 
